Search

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Opioids. According to news originating from Aurora, [...]

2024 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Obesity, Fitness and Wellness. According to news [...]

2024 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Non-Steroidal Anti-Inflammatory Agents have [...]

2021 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

2021 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Opioids. According to news reporting from New [...]

2021 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

2021 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

2021 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Colon Cancer have been published. According [...]

Peptic ulcer disease (PUD) is a common disorder in the United States, with approximately 500,000 new cases diagnosed each year and 4 million cases of ulcer recurrence. (1) Complications related [...]

Peptic ulcer disease (PUD) is a common disorder in the United States, with approximately 500,000 new cases diagnosed each year and 4 million cases of ulcer recurrence. (1) Complications related [...]

The International Society of Feline Medicine (ISFM) and the American Association of Feline Practitioners (AAFP) recently published a set of guidelines for the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) [...]

Purpose: To examine the benefits and harms of nonaspirin (non-ASA) nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX-2) inhibitors for the prevention of colorectal cancer (CRC) and adenoma. Data Sources: MEDLINE (1966 to 2006), EMBASE (1980 to 2006), Cochrane Central Register of Controlled Trials, Cochrane Collaboration's registry of clinical trials, Cochrane Database of Systematic Reviews. Study Selection: Randomized, controlled trials and case-control and cohort studies of the effectiveness of NSAIDs for the prevention of CRC and colorectal adenoma were identified by multilevel screening by 2 independent reviewers. Systematic reviews of harms were sought. Data Extraction: Data abstraction, checking, and quality assessment were completed in duplicate. Data Synthesis: A single cohort study showed no effect of non-ASA NSAIDs on death due to CRC. Colorectal cancer incidence was reduced with non-ASA NSAIDs in cohort studies (relative risk, 0.61 [95% CI, 0.48 to 0.77]) and case-control studies (relative risk, 0.70 [CI, 0.63 to 0.78]). Colorectal adenoma incidence was also reduced with non-ASA NSAID use in cohort studies (relative risk, 0.64 [CI, 0.48 to 0.85]) and case-control studies (relative risk, 0.54 [CI, 0.4 to 0.74]) and by COX-2 inhibitors in randomized, controlled trials (relative risk, 0.72 [CI, 0.68 to 0.77]). The ulcer complication rate associated with non-ASA NSAIDs is 1.5% per year. Compared with non-ASA NSAIDs, COX-2 inhibitors reduce this risk but, in multi-year use, have a higher ulcer complication rate than placebo. Cyclooxygenase-2 inhibitors and nonnaproxen NSAIDs increase the risk for serious cardiovascular events (relative risk, 1.86 [CI, 1.33 to 2.59] for COX-2 inhibitors vs. placebo). Limitations: Heterogeneity in the dose, duration and frequency of use necessitated careful grouping for analysis. Conclusions: Cyclooxygenase-2 inhibitors and NSAIDs reduce the incidence of colonic adenomas. Nonsteroidal anti-inflammatory drugs also reduce the incidence of CRC. However, these agents are associated with important cardiovascular events and gastrointestinal harms. The balance of benefits to risk does not favor chemoprevention in average-risk individuals.

The adverse effects of cardiovascular (CV) related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) are examined. Findings recommend the usage of all NSAIDs in the lowest effective dosage with caution in high-risk CV patients.

The decision-making process of determining the use of coxibs and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) is discussed. Findings reveal that coxibs is suitable for patients with increased gastrointestinal (GI) risk.

Practice recommendation * Though all non-narcotic analgesics have equivalent efficacy against tension-type headache, ibuprofen's generally favorable side-effect profile makes it a reasonable first choice. Whereas quantitative and qualitative analyses of [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2005.10.056 Byline: Shelley R. Salpeter (a)(b), Peter Gregor (b), Thomas M. Ormiston (b), Richard Whitlock (c), Parminder Raina (c)(d), Lehana Thabane (d)(e), Eric J. Topol (f) Keywords: Non-steroidal anti-inflammatory agents; Cyclooxygenase-2 inhibitors; Cardiovascular disease; Meta-analysis Abstract: We performed a meta-analysis of randomized controlled trials to assess the effect of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) on cardiovascular events in trials of joint disease and Alzheimer's disease. Author Affiliation: (a) Stanford University School of Medicine, Stanford, Calif (b) Santa Clara Valley Medical Center, San Jose, Calif (c) McMaster Evidence-based Practice Centre, McMaster University, Hamilton, Ont, Canada (d) Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont, Canada (e) Centre for Evaluation of Medicines, Saint Joseph's Healthcare, Hamilton, Ont, Canada (f) Department of Genetics, Case Western Reserve University, Cleveland, Ohio Article Note: (footnote) None of the authors have any relationships with a manufacturer of NSAIDs or COX-2 inhibitors at present. Parminder Raina has held a grant from Merck Frost Canada in the past. Shelley Salpeter served as a consultant for Wyeth and was paid on an hourly basis. Peter Gregor served on the speaker's bureau for Dupont before 2002.

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues. Overexpression of COX-2 increases cell proliferation and inhibits apoptosis. However, selective COX-2 inhibitors can also act through COX-independent mechanisms. In this review, we describe the COX-2-independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors. We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.